Conference Coverage
Latest News
Nov 04, 2026 | Commentary
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
Nov 04, 2026
Infertility care: Examining geographic gaps in access
Nov 04, 2026
Aaron Berger, MD, discusses considerations for ARPI treatment breaks
Nov 03, 2026
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
Nov 03, 2026
Advertisement
Shorts
0:39
Making the most of networking at the LUGPA Annual Meeting
2 days ago
by
Benjamin H. Lowentritt, MD, FACS
0:20
New guidelines recognize penoscrotal decompression for priapism
3 days ago
by
Juan J. Andino, MD, MBA
0:35
Administrators, coordinators, and lab directors at LUGPA
6 days ago
by
Benjamin H. Lowentritt, MD, FACS
0:30
Expert: Belzutifan plus lenvatinib advances outcomes in advanced ccRCC
7 days ago
by
Daniel Heng, MD, MPH, FRCPC
0:57
What urine cell-free RNA can reveal about bladder cancer
8 days ago
by
Maximilian Diehn, MD, PhD
0:26
When voiding difficulty points to underactive bladder
9 days ago
by
Ariana L. Smith, MD
0:26
Dr. Lowentritt's LUGPA 2027 pick: Friday afternoon breakouts
10 days ago
by
Benjamin H. Lowentritt, MD, FACS
0:30
Correcting misconceptions about hormone therapy for GSM
14 days ago
by
Engy Habashy, MD
1:29
How gravity instillation may improve gem/doce feasibility
15 days ago
by
Adam B. Weiner, MD(+1 more)
0:50
Expert: Anktiva approval sets precedent for papillary-only NMIBC
16 days ago
by
JJ Zhang, MD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Advertisement
Topline results from the study are anticipated in the first half of 2027.
The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5